Related Experiment Video

Updated: Aug 18, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

Epidermal growth factor receptor-targeted treatment for advanced colorectal carcinoma

Alan P Venook1

  • 1Department of Medicine, University of California-San Francisco, San Francisco, California 94115, USA. venhook@cc.ucsf.edu

Cancer
|May 10, 2005
PubMed

Insights

Novel targeted agents are being developed to treat advanced colorectal carcinoma by inhibiting specific biochemical pathways. Epidermal growth factor receptor inhibitors show promise in changing treatment approaches for this cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Late-stage colorectal carcinoma presents significant treatment challenges.
  • Targeted therapies offer a promising avenue for improving patient outcomes.
  • Understanding pathogenic biochemical processes is crucial for developing effective treatments.

Purpose of the Study:

  • To review the development of novel targeted agents for advanced colorectal carcinoma.
  • To highlight the role of agents targeting the epidermal growth factor receptor (EGFR).
  • To discuss the potential shift in treatment paradigms for colorectal carcinoma.

Main Methods:

  • Review of current research and clinical investigations.
  • Analysis of targeted agents focusing on specific biochemical pathways.
  • Evaluation of epidermal growth factor receptor inhibitors in colorectal cancer treatment.

Main Results:

  • Development of novel targeted agents for late-stage colorectal carcinoma is ongoing.
  • Epidermal growth factor receptor (EGFR) targeted molecules are a key focus.
  • These targeted agents aim to inhibit specific pathogenic biochemical processes.

Conclusions:

  • Targeted agents represent a significant advancement in treating advanced colorectal carcinoma.
  • Epidermal growth factor receptor (EGFR) inhibitors are emerging as important therapeutic options.
  • These developments suggest a potential paradigm shift in colorectal carcinoma treatment strategies.

More Related Videos

Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles08:35

Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles

Published on: January 4, 2012

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...